HAEMAPHERESIS VIGILANCE: FIRST RESULTS OF AN INTERNATIONAL INTERNET-BASED SYSTEM TO ASSESS DONOR COMPLICATIONS DURING OR AFTER HAEMAPHERESIS PROCEDURES

H.G. Heuft, H. Baume, T. Burkhardt, U. Diekamp, M. Funk, L. Goudeva, H. Kroll, G. Leitner, B. Mansouri-Taleghani, U. Reinicke-Voigt, J. Schmidt, E. Strasser, T. Weingand, G. Wittmann, R. Tutte, E.G. Fischer

The Haemapheresis Vigilance Working Party of the German Society for Transfusion Medicine and Immunohaematology (DGTI)

Purpose

To assess donor- and/or apheresis-complications related to preparative haemaphereses: a simple, safe, and effective international Internet-based system has been developed: http://haemapheresisvigilance.eu

Methods

All complications (e. g. venous access and circulation problems, citrate toxicity, donor compliance and some technical complications), are assessed with respect to preparative plasmapheresis, platelet apheresis, leukapheresis (blood stem cells, granulocytes, monocytes), red cell apheresis and multicomponent apheresis from healthy donors. The complications are evaluated according to the International Haemovigilance Network Standards. To avoid operator-specific interindividual variability the grading for mild, moderate or severe undesired events are based on the operator's interventions rather than on the operator's subjective estimation of the severity of the complication. An automatic evaluation program will allow comparing the centre-specific complication rate with corresponding rates of other centres from the same institution as well as with a national benchmark. The system is supported by the German Society for Transfusion Medicine and Immunohaematology (DGTI).

Results and Discussion

Currently, 20 centres (Austria, n=1, Germany, n=15 and Switzerland, n=4) use the system. For data assessment two HTML pages are available: one page that collects donor variables (e. g. gender, body weight, blood volume) and offers clickable submenues to assess technical characteristics of the planned apheresis procedure (e. g. platelet apheresis, see Fig. 1). The second page is designed for collecting specific information about the complication and its severity (Fig. 2a / 2b). The upper part of this HTLM page records discontinuations and the consequences of this event for the donor (e.g. red cell losses), the set and product logistics (e. g. available products despite discontinuation; Fig. 2a). The middle and lower part of this page include clickable submenues that summarize specific complications (e. g. venous access problems, citrate toxicity, circulation reactions, donor compliance, Fig. 2a) and assess the severity of the complication by an underlying automatical algorithm that combines donor symptoms and medical staff interventions to control the complication. These masks are supported by an entry-control and by an automated evaluation system that is visible for center related authorized personnel only, see here preparative platelet aphereses, January through November, 2012, Fig. 2b).

From January 23, 2012 to December 31, 2012 a total of 4.630 reactions have been recorded to the system. The distribution to different apheresis techniques was 54% for plasmaphereses, 40% for plateletphereses, 5% for stem cell aphereses, other aphereses (granulocytes, lymphocytes, monocytes) ≤1%. The registered undesired events consisted of venous access problems (n=2533; 54.7%), citrate toxicity (n=744; 16.1%), circulation reactions (n=508; 11.0%), donor compliance problems (n=727; 15.7%), technical (apheresis machine or apheresis disposable related) problems (n=453, 9.8%) and combined events comprising at least two events simultaneously (e. g. venous access problem plus circulation reaction, n=416; 9.0%). The reactions were graded as mild 83.6%, moderate 14.7% or severe 1.7%. However, severe reactions associated with hospital stays, injuries lasting one year or more or death were never observed.

Conclusions

This Internet based platform provides a simple, safe and useful tool to assess and to evaluate all relevant complications associated with preparative haemapheresis procedures.

Killes di - Apheresis viplance 🔅					
	Donation ID		Continuous system ID	Donation data	
			11216589	23.01.2013	
5 Dener ID	D 993038983				
1.1 Gender	C male R female				
1.2 Year of bith	1971				
1.3 Height	163 cm		04.00 inch	EMI: 23 kg/m ²	
1.4 Weight	61.00 kg		134.50 lbs	TBV: 4157 ml	
14 Denor type	C patient C first-time blood damar C first-time aphanesis damar		C first time aphenesis type donor P multiple aphenesis donor		
18 Regular medication	anti-hypertension therapy				
	F PLT) C SC	T C PMN) 🧖 Red cell concentrate) C MAC	
PLS Platebet aphenosis 23.9 Pracedae 23.2 Therapeyic units 23.9 Plasma-reductd 23.4 Yolume substitution	tize defeative values :	Γ two arms procedure Φ double Φ to Φ to Φ to	Ctriple) e sos	
PLS Platelet aphaeesis Tolka Zz7 Principle 222 Principle Zz3 Platenepic units Zz3 Platenepic units	lize defeadt values :F on am-providure C single C yos	⊂ two-armo-procedure Probabile Prop Prop Cranal SCD mg	Criple) e 1000	
PLS Platebet aphenosis 23.9 Pracedae 23.2 Therapeyic units 23.9 Plasma-reductd 23.4 Yolume substitution	tize defeative values :	Γ two arms procedure Φ double Φ to Φ to Φ to	Crople Coal LCOD mp Crock cells) C 105	
C PLS Interference in the interference in the interference in the interference in the interference interferen	Non-disfacill variances =	C ten arres guccolars d'optr d'op d'aro C ar statisti c'ara 500 mg C planno C'planno C'planno ≠ nol cell	Crople Coal LCOD mp Crock cells) ° мж	

Figure 1 Donor and Procedure related Data (e.g. platelet apheresis)

	Danation ID			Continuous system	ID Danation da		
	1 8 1 8 1 18 1 18 8 18 18 18 18 18 18 18			11210589	23.01.201		
Donor ID	10	9900008883					
		Event without termination					
A Course of aphenesis		Termination, but all planned products are a	btained	C Termination, but all planned products are obtained, no reinfusion			
		C Termination, planned products are only obtained partly		C Termination, planned products are only obtained partly, no reinfasion			
		* Termination, no useful products					
42 Obtained	3	72 ml of planned 450 ml					
	3	190.00 10 ⁹ Cells of planned 500.00 10 ⁹ Cells					
	r	Plasma for fractionation (no by-product)					
	r	F1 F2 F3 P(Stee)					
	r	E1 E2 E3 thrombecates (PLT)					
a Therapeutic units for homan une	r	1 2 red cells					
or roman day	r	stem cells		E granula cytes (PMN)			
	r	lymphocytes		E manacytes			
		first C second C third+last part af-	apa electra s				
* (Specification of the event		after the ond of ophonesis Cafter loads	aphenosis ig the institute				
* Specification of the overt		after the end of ophenesis after loavin	asserous ig the institute	Techers) Conve		
P Parchase T F Anto		after the end of ophenesis after loavin	g the institute) 🗖 Tataks	Ť∎ mos		
P Pastare T Annual Participation of the Annual Participati	unitite	Cather the end of ophenesis Cather lower	g the institute) 🗖 terres) F. const		
P Pastare T Annual Participation of the Annual Participati	outbles oural puncture 「paravi	Saber He and of ophoresis C after loave	g the institute) P. const		
P Pastare T Annual Participation of the Annual Participati	unitite	Star the ord of ophonesis C shar lower T Constitution inclus puncture accele po	ig the institute □ □ Danase in □ for < 20 min	C > 20 min	T max		
P Parture Parture Produce Parture Product of Puncture Product puncture To	outbles oural puncture 「paravi	atter the ord of spheresis C after lower C Descentes mous puncture C for < 14 days	in C for < 20 min C > 14 days	C > 20 min C > 12 months			
Pastare P	analaten auralpunture Eparan 6 aa	Inter the ond of spheresis C after loave C after loave mous puncture C for < 14 days C solar latester	in C for < 20 min C > 14 days	C > 20 min C > 12 months □ threesbaphiebdis	Coccurred with delay =		
P Parture Parture Produce Parture Product of Puncture Product puncture To	evalpunture Eparan	Table the end of optimiss C attact loave The concatering C attact loave The concatering Attact loave The concatering Attact loave C for c 14 days Totact loave C for c 14 days Totact loave	in C for < 20 min C > 14 days C > 24 days C > 20 min	C > 20 min C > 12 months C threedup/liebits C > 50 mm	□ occurred with delay " □ > 100 mm		
Pastare P	evalpunture Eparan	Inter the ond of spheresis C after loave C after loave mous puncture C for < 14 days C solar latester	in C for < 20 min C > 14 days	C > 20 min C > 12 months C threedup/liebits C > 50 mm	Coccurred with delay =		
Parate Function of the second	eural puncture F paravi e au F as F perfet	Table the end of optimiss C attact loave The concatering C attact loave The concatering Attact loave The concatering Attact loave C for c 14 days Totact loave C for c 14 days Totact loave	in C for < 20 min C > 14 days C > 24 days C > 20 min	C > 20 min C > 12 months C threedup/liebits C > 50 mm	C occurred with delay " C > 000 mm C occurred with delay "		
Particle Particle Provide content of Particle Particle content of Particle Particle contents Particle contents Particle incohere acta Particle Particle Acta Particle Pa	oural puncture F parant F as F parant F parant F	after the end of opportunity Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints Constraints C	in C for <20 min C > 14 days C > 20 mm C > 20 mm C > 20 mm	C > 20 min C > 12 months E threesing/likelits C > 50 mm corre	□ occurred with delay " □ > 100 mm		

Figure 2a Discontinuation, unsuccessful phlebotomy at Hannover Medical School

proparative "Pointer Advancess (PLT) processage for using wave pairvesses of the May 664 ff in full years 2012 baced an CPT agatheress in full forms years							
			nit note	de all severe	sovere >1x	total	Þ
4.	Complications mainly with local symptoms [1]						
4.1.	Complications mainly characterized by the occurrence of blood outside the v	essels.					
41.1	Haematoma	1.1.%		0 %	0.%	1.6 %	
1.2	Arterial puncture	1 0 %	0%	0%	0 %	0%	
1.3	Delayed bleeding	1 0 %	0%	0%	0%	0%	
42	Complications mainly characterized by pain						
A21	Nerve initiation	1 0 %	0%	0%	0.%	0%	
422	Nerve injury	1 0 %	0%	0%	0.%	0%	
423	Tendas injury	1 8.8	5.8.	5.8.	na.	8.8.	
4.2.4	Paint/ am	1 0.8	P. 8.	5.3	n.a.	0.0	
43	Other complications with local symptoms						
431	Thromboohiebtis	1 0 %	0 %	0%	0%	0%	-
432	Alleray docab	1 8.9	0.8.	6.8.	0.8	8.4	
433	Local pain, infection or inflammation	1.1%	0.4 %	0%	0.%	14.%	
4.total	Total number local symptems (according to FN without A.3.3)	1.12.1	0.44 %	0.05 %	0 %	1.62 %	
3	Complications mainly with generalized symptoms. [1]						
3.1	Immediate Vasovagal reaction	1 0.4 %	0.1 %	0%	0.%	0.6 %	
12	Immediate Vasovagal Reaction with Inkny	1 0 %	0%	0%	0%	0%	
3.3	Delayed Vapovepal Reaction	1 0 %	0%	0%	0 %	0%	
3.4	Delayed Vacavapal Reaction with injury	1 0 %	0%	0%	0.%	0%	
3 total	Total number of Vanovagal Reactions	0.4 %	0.14 %	0.05 %	0.%	0.59 %	
	Further Complications						
Ċ.1	Citrate reaction	0.2 %	0.1 %	0%	0 %	0.3 %	
2	Haemolesis	0 %	0 %	0%	0%	0%	
.3	Generalised alleraic maction	0.9	6.8.	6.4.	0.9.	5.3.	
0.4	Air embolism	0.8	5.8	5.8.	0.8	5.8	
)	Other complications related to blood denation						
)	donar compliance	0.8 %	0.1 %	0 %	0 %	0.9 %	
	Technical complications related to blood donation						
	technical complications	1 0.4 %	0.2 %	0.1 %	0 %	0.7 %	
total .		3.84 1		0.26 %	0 %	5.43 %	
Jotal accord	ng to IHN-Annex 4. (without A.3.3, D and E)	1.73 5	0.66 %	0.09 %	0 %	2.51 %	

Figure 2b Evaluation according to IHN Standard, here platelet aphereses, collected from 01/2012 – 11/2012.

Hannover Medical School, Institute for Transfusion Medicine, OE 8350 Carl-Neuberg-Straße 1, 30625 Hannover Heuft.Hans-Gert@MH-Hannover.de, www.mh-hannover.de